Insider Transactions in Q4 2021 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2021
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.13%
|
$173,250
$18.75 P/Share
|
|
Dec 16
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
200
-0.85%
|
$4,000
$20.0 P/Share
|
|
Dec 16
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
200
+0.84%
|
-
|
|
Dec 16
2021
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
2,500
-1.69%
|
$47,500
$19.01 P/Share
|
|
Dec 13
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.42%
|
$2,000
$20.02 P/Share
|
|
Dec 13
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100
+0.42%
|
-
|
|
Dec 09
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,086
-4.42%
|
$21,720
$20.01 P/Share
|
|
Dec 09
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
1,086
+4.24%
|
-
|
|
Dec 08
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,664
-18.51%
|
$213,280
$20.15 P/Share
|
|
Dec 08
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
5,488
+15.93%
|
-
|
|
Dec 08
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,646
+50.0%
|
$57,292
$2.47 P/Share
|
|
Dec 07
2021
|
Lux Ventures Iv, L.P. |
SELL
Other acquisition or disposition
|
Direct |
4,265,576
-24.67%
|
-
|
|
Dec 07
2021
|
Zavain Dar Director |
BUY
Other acquisition or disposition
|
Direct |
3,599
+50.0%
|
-
|
|
Dec 07
2021
|
Dean Y Li Director |
SELL
Open market or private sale
|
Indirect |
15,900
-0.6%
|
$318,000
$20.75 P/Share
|
|
Dec 07
2021
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.04%
|
$192,500
$20.4 P/Share
|
|
Dec 07
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
3,125
-1.04%
|
$62,500
$20.78 P/Share
|
|
Dec 07
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,667
-0.1%
|
$333,340
$20.75 P/Share
|
|
Nov 21
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
1,100,000
+50.0%
|
-
|
|
Nov 21
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,100,000
-11.81%
|
-
|
|
Nov 19
2021
|
Dean Y Li Director |
SELL
Open market or private sale
|
Direct |
13,474
-2.28%
|
$269,480
$20.2 P/Share
|
|
Nov 18
2021
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.06%
|
$173,250
$18.68 P/Share
|
|
Nov 18
2021
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
2,500
-2.4%
|
$47,500
$19.01 P/Share
|
|
Nov 17
2021
|
Dean Y Li Director |
SELL
Open market or private sale
|
Direct |
5,626
-0.94%
|
$112,520
$20.04 P/Share
|
|
Oct 01
2021
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
543
+0.09%
|
-
|
|
Oct 01
2021
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
457
+0.01%
|
-
|
|
Oct 01
2021
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
295
+27.42%
|
-
|
|
Oct 01
2021
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
572
+7.39%
|
-
|
|
Oct 01
2021
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
629
+0.47%
|
-
|
|
Oct 01
2021
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
858
+10.11%
|
-
|